

a pharmaceutically-acceptable carrier, wherein the preparation is formulated as a unit dosage containing the conjugate in an amount effective for activating the immune response of a mammal when administered to an apical surface of an epithelial barrier of the mammal, and wherein the pharmaceutical preparation is an oral formulation, an aerosol formulation or a nasal formulation.

Remarks

Applicants have amended the claims to more particularly and distinctly claim the invention. This is not a narrowing amendment. Instead, the amendment is simply meant to clarify what applicants have meant all along. No new matter has been added.

Respectfully submitted,

By: Edward R. Gates
Edward R. Gates, Reg No. 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. S1383/7003 (ERG)
Dated: April 10, 2001
xNDD

526645.1

75

E